Details of the Drug Combinations

General Information of This Drug (ID: DM7W94S)

Drug Name

Brigatinib DM7W94S

Synonyms

1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958

Indication

Disease Entry	ICD 11	Status	REF
Anaplastic large cell lymphoma	2A90.A	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Arry-162 + Brigatinib	DCPHL38	Arry-162	ALK Gene Rearrangement	[3]
Brigatinib + Midazolam	DCTEAXU	Midazolam	Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors	[4]
Brigatinib + Ceritinib	DCJW560	Ceritinib	Lung Non-Squamous Non-Small Cell Carcinoma	[5]
Brigatinib + Lorlatinib	DC8OILK	Lorlatinib	Lung Non-Squamous Non-Small Cell Carcinoma	[5]
------------------------------------------------------------------------------------

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
3	ClinicalTrials.gov (NCT04005144) Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
4	ClinicalTrials.gov (NCT03420742) A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
5	ClinicalTrials.gov (NCT03737994) Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer